Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple dose levels of IPI-145 with background methotrexate in active rheumatoid arthritis
2012-003724-20Phase 2Completed
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing IPI-145 + methotrexate with Placebo + methotrexate (2 arms). Primary endpoint: ACR20 response at Week 12. Started Dec 2012; status: completed.
02
Drugs
duvelisib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-003724-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003724-20.